Latest Breaking News On - John kastelein - Page 1 : comparemela.com

NewAmsterdam Pharma (NAMS) Announces Initial Data from Phase 2a Clinical Trial of Obicetrapib

NewAmsterdam Pharma (NAMS) Announces Initial Data from Phase 2a Clinical Trial of Obicetrapib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Las-vegas
Michael-davidson
John-kastelein
Jeffrey-cummings
Drug-administration
Grundy-center
University-of-nevada
Newamsterdam-pharma-companynv-nasdaq
Chambers-grundy-center
Transformative-neuroscience
Chief-executive-officer
Chief-scientific-officer

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation

Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid , respectively, indicating potential improvement of cholesterol metabolism in the brain Observed 8%.

Brooklyn
Florida
United-states
Netherlands
Naarden
Noord-holland
Ukraine
Russia
Miami
John-kastelein
Las-vegas
Jeffrey-cummings

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United-states
Brooklyn
Florida
China
Naarden
Noord-holland
Netherlands
Japan
Ukraine
Miami
Russia
Michael-davidson

Combination Obicetrapib plus Ezetimibe Shows Promise for Dyslipidemia in Phase 2 Trial

New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.

John-kastelein
Christiem-ballantyne
York-heart-association-functional-classification-class
National-lipid-association
Newamsterdam-pharma-company
Baylor-college-of-medicine
Cardiovascular-research
Baylor-college-of-medicine-christie-ballantyne
Baylor-college
Christie-ballantyne
Scientific-sessions
Consensus-decision-pathway

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

The CETP inhibitor’s development checked another box, with investigators showing it works when added to existing therapies.

Monash
South-australia
Australia
Baylor-college-of-medicine
Texas
United-states
Houston
John-kastelein
Christie-ballantyne
Stephen-nicholls
Michael-davidson
Amgen